ArticleInternational journal of biomaterials2026
Dual Graphene Oxide-Based Multigene Delivery for Cancer Elimination via Stromal and Immune Reprogramming.
Article in International journal of biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer therapies are often limited by poor cellular specificity and tumor microenvironment-mediated immunosuppression. We developed a dual-function graphene oxide (GO)-based gene delivery platform combining direct cancer cell elimination with stromal and immune reprogramming. CD47-targeting siRNA and ANT1-encoding plasmid DNA selectively induced apoptosis in tumor cells, while TGFβ-targeting siRNA altered cancer-associated fibroblasts (CAFs) phenotype and was associated with a shift in macrophage polarization toward a pro-inflammatory, tumor-restraining phenotype. We evaluated this approach in a 3D multicellular lung cancer model consisting of A549 cells, human lung fibroblasts, and THP1-derived macrophages. TGFβ silencing alone modulated stromal and immune features without direct cytotoxicity, whereas CD47/ANT1 modulation reduced overall cell viability to ∼51%. When both therapeutic functions were applied together, overall cell viability was further reduced to ∼29%. EGFR-targeted GO-CD47-ANT1 (GE11-peptide modified formulation) enhanced tumor-cell uptake and selective apoptosis in CK7
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.